Hirokawa S, Nose M, Ishige A, Amagaya S, Ogihara Y
Faculty of Pharmaceutical Sciences, Nagoya City University, Japan.
Biol Pharm Bull. 1994 Sep;17(9):1182-6. doi: 10.1248/bpb.17.1182.
The effect of Hachimijiogan on cognitive disturbance was investigated using step-through passive avoidance failure techniques: scopolamine-, cycloheximide- and cerebral ischemia-induced amnesia. Pre-acquisition trial administration of Hachimijiogan (0.5 g/kg, p.o.) prolonged the step-through latency reduced by scopolamine and cycloheximide. Hachimijiogan (0.5 and 1.0 g/kg, p.o.) also ameliorated the cerebral ischemia-induced amnesia. Physostigmine (0.1 mg/kg, i.p.) ameliorated all three amnesia models. The ameliorating effects of Hachimijiogan and physostigmine on cycloheximide-induced amnesia were diminished by the combination with scopolamine. These results suggest that Hachimijiogan possesses a wide-ranging pharmacological profile in anti-amnesic actions and that its anti-amnesic activities may be related to the cholinergic neuronal system.